Therefore, we performed this study to identify clinicopathological factors associated with PD-L1 expression in tumour cells and PD-1 expression in TILs in early breast cancer and to reveal the association between clinical outcomes and PD-L1 or PD-1 expression. The gene discussed is PDCD1; the disease is breast carcinoma.